Zacks Research Issues Pessimistic Estimate for PBYI Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities researchers at Zacks Research dropped their Q1 2027 earnings per share (EPS) estimates for Puma Biotechnology in a research report issued to clients and investors on Friday, January 16th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $0.08 per share for the quarter, down from their prior forecast of $0.09. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q3 2027 earnings at $0.07 EPS.

Several other research analysts have also weighed in on PBYI. Weiss Ratings lowered shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Puma Biotechnology has an average rating of “Moderate Buy” and an average price target of $7.00.

Puma Biotechnology Trading Down 0.2%

NASDAQ:PBYI opened at $6.37 on Monday. The firm’s fifty day simple moving average is $5.59 and its 200 day simple moving average is $4.93. Puma Biotechnology has a twelve month low of $2.58 and a twelve month high of $6.48. The firm has a market capitalization of $320.98 million, a price-to-earnings ratio of 8.61 and a beta of 1.19.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.12. Puma Biotechnology had a net margin of 17.45% and a return on equity of 36.17%. The company had revenue of $54.48 million during the quarter, compared to the consensus estimate of $51.00 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. raised its holdings in Puma Biotechnology by 88.9% during the first quarter. Invesco Ltd. now owns 37,631 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 17,707 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Puma Biotechnology by 3.8% in the 1st quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 3,117 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Puma Biotechnology by 366.5% in the 1st quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 39,641 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Puma Biotechnology in the first quarter valued at $66,000. Finally, Strs Ohio bought a new position in Puma Biotechnology during the first quarter valued at about $420,000. 61.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Puma Biotechnology

In related news, insider Douglas M. Hunt sold 5,014 shares of Puma Biotechnology stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total transaction of $29,482.32. Following the sale, the insider directly owned 155,907 shares in the company, valued at $916,733.16. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Alan H. Auerbach sold 18,012 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total transaction of $105,910.56. Following the transaction, the chief executive officer directly owned 7,145,951 shares in the company, valued at approximately $42,018,191.88. The trade was a 0.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 63,937 shares of company stock valued at $354,713 in the last ninety days. Company insiders own 23.30% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.